Correlations between clinicopathological parameters and molecular signatures of primary tumors for patients with stage T3N0 colorectal adenocarcinomas: A single center retrospective study on 100 cases

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 1091-1097

  András, Csilla ^a   Tóth, László ^b   Molnár, Csaba ^b   Tanyi, Miklós ^a   Csiki, Zoltán ^a   Dezsõ, Balázs ^b   Pósán, János ^a   Shemirani, Amir Houshang ^a   Csiki, Emese ^a   Szántó, János ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Colorectal cancer; Metastasis; Prognostic markers; TMA

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P16; PROTEIN P21; PROTEIN P53; THYMIDYLATE SYNTHASE; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CARCINOMA; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861349904     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12041     Document Type: Article

References (30)

1. Herszenyi L, Tulassay Z: Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14:249-258.
2. Morris M, Platell C, de Boer B, et al.: Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006; 93:866-871.
3. Andre T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-3116.
4. Andre T, de Gramont A: An overview of adjuvant systemic chemotherapy for colon cancer. Clin Colorectal Cancer 2004; 4:S22-28.
5. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420-1425.
6. Fernebro E, Dictor M, Bendahl PO, Ferno M, Nilbert M: Evaluation of the tissue microarray technique for immunohisto-chemical analysis in rectal cancer. Arch Pathol Lab Med 2002; 126:702-705.
7. Hoos A, Nissan A, Stojadinovic A, et al.: Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 2002; 8:3841-3849.
8. Spaulding DC, Spaulding BO: Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 2002; 29:45-54.
9. Lindebjerg J, Nielsen JN, Hoeffding LD, Jakobsen A: Immuno-histochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. APMIS 2005; 113:600-602.
10. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL: Prognostic and diagnostic significance of beta-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 2004; 10:1401-1408.
11. Swanson RS, Compton CC, Stewart AK, Bland KI: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10:65-71.
12. Benson AB, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-3419.
13. Kern SE, Fearon ER, Tersmette KW, et al.: Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 1989; 261:3099-3103.
14. Mottolese M, Buglioli S, Piperno G, et al.: Bio-pathological factors of prognostic value in colorectal adenocarcinomas. J Exp Clin Cancer Res 2003; 22:163-166.
15. Garrity MM, Burgart LJ, Mahoney MR, et al.: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 over expression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004; 22:1572-1582.
16. Goh HS, Elnatan J, Low CH, Smith DR: p53 point mutation and survival in colorectal cancer patients: effect of disease dissemination and tumor location. Int J Oncol 1999; 15:491-498.
17. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M: The results of colorectal cancer treatment by p53 status: treatment-specific overview. Dis Colon Rectum 2001; 44:322-333.
18. Xu G, Wang HF, He G: Expression and significance of P53 and P21 in nasal NK/T-cell lymphoma. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41:132-136.
19. Noske A, Lipka S, Budczies J, et al.: Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer. Oncol Rep 2009; 22:3-9.
20. Carneiro FP, Ramalho LN, Britto-Garcia S, et al.: Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum 2006; 49:588-594.
21. Lam AK, Ong K, Giv MJ, Ho YH: p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 2008; 40:580-585.
22. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K: The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 2008; 28:3815-3826.
23. Lugli A, Zlobec I, Minoo P, et al.: Prognostic significance of the Wnt signaling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology 2007; 50:453-464.
24. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M: E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77:1605-1613.
25. Delektorskaia VV, Perevoshchikov AG, Kushlinskii NE: The features of expression of cellular adhesion molecules in primary colorectal cancer and its metastases. Vopr Onkol 2005; 51:328-333.
26. Ilyas M: Wnt signaling and the mechanistic basis of tumor development. J Pathol 2005; 205:130-144.
27. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004; 10:3069-3075.
28. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-257.
29. Popat S, Hubner R, Houlston RS: Systematic review of micro-satellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23:609-618.
30. Broll R, Busch P, Duchrow M, et al.: Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. Int J Colorectal Dis 2005; 20:94-102.